ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Humacyte, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class action lawsuit pertains to securities purchased between May 10, 2024, and October 17, 2024, with a lead plaintiff deadline set for January 17, 2025 [1][2]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. Group 2: Case Allegations - The lawsuit alleges that Humacyte made false or misleading statements regarding its Durham, North Carolina facility's compliance with good manufacturing practices, which included quality assurance and microbial testing [4]. - It is claimed that the FDA's review of Humacyte's Biologics License Application would be delayed due to these compliance issues, posing a substantial risk to the approval of Acellular Tissue Engineered Vessel for vascular trauma [4]. - The lawsuit asserts that the positive statements made by Humacyte about its business and prospects were materially misleading and lacked a reasonable basis, resulting in investor damages when the truth was revealed [4]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for the number of securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3].